RGNX
REGENXBIO Inc.
Key Financials
Net Income
$-193878000
↑ 14.6%
Operating Income
$-161198000
↑ 30.9%
Revenue
$170.4M
↑ 104.5%
EPS (Diluted)
$-3.76
↑ 18.1%
Shareholders' Equity
$102.7M
↓ 60.4%
Total Assets
$453.0M
↓ 2.8%
Cash & Equivalents
$34.5M
↓ 40.1%
Total Liabilities
$350.3M
↑ 69.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/23/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 4 | 8/27/2026 | View on SEC |
| 3 | 8/27/2026 | View on SEC |
| 8-K | 8/25/2026 | View on SEC |
| 8-K | 8/24/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RGNX |
| Company Name | REGENXBIO Inc. |
| CIK | 1590877 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 240-552-8181 |